{"doi":"10.4137/cmo.s1590","title":"Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors","abstract":"<jats:p>The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimus and temsirolimus, both approved for distinct indications in mRCC. Everolimus gained its approval on the basis of phase III data showing a benefit in progression-free survival relative to placebo in patients previously treated with sunitinib and/or sorafenib. In contrast, temsirolimus was approved on the basis of a phase III trial in treatment-naïve patients with poor-risk mRCC, demonstrating an improvement in overall survival relative to interferon-alfa. While these pivotal trials have created unique positions for everolimus and temsirolimus in current clinical algorithms, the role of mTOR inhibitors in mRCC is being steadily revised and expanded through ongoing trials testing novel sequences and combinations. The clinical development of mTOR inhibitors is outlined herein.</jats:p>","journal":"Clinical Medicine Insights: Oncology","year":2010,"id":654538,"datarank":0.40620753016533157,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.0,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":14,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1181999,"name":"Robert A. Figlin","orcid":null,"position":1,"is_corresponding":false},{"id":1708258,"name":"Sumanta Kumar Pal","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors","abstract":"<jats:p>The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimus and temsirolimus, both approved for distinct indications in mRCC. Everolimus gained its approval on the basis of phase III data showing a benefit in progression-free survival relative to placebo in patients previously treated with sunitinib and/or sorafenib. In contrast, temsirolimus was approved on the basis of a phase III trial in treatment-naïve patients with poor-risk mRCC, demonstrating an improvement in overall survival relative to interferon-alfa. While these pivotal trials have created unique positions for everolimus and temsirolimus in current clinical algorithms, the role of mTOR inhibitors in mRCC is being steadily revised and expanded through ongoing trials testing novel sequences and combinations. The clinical development of mTOR inhibitors is outlined herein.</jats:p>","is_dataset_classified":null,"base_score":2.70805020110221,"endowment":2.70805020110221,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20711245","pmcid":"PMC2902205","openalex_id":"https://openalex.org/W2100511392","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"K12 CA001727","title":null},{"funder_name":"National Institutes of Health","grant_id":"2K12CA001727-16A1","title":"City of Hope Clinical Oncology Career Research Development Program"}],"total_grants":2,"fwci":2.208,"citation_percentile":0.87830977,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":1},{"year":2017,"count":1},{"year":2019,"count":1},{"year":2023,"count":1},{"year":2025,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.4137/CMO.S1590","host_type":"journal"},{"url":"https://journals.sagepub.com/doi/pdf/10.4137/CMO.S1590","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/full-xml/10.4137/CMO.S1590","host_type":"publisher"},{"url":"https://doi.org/10.4137/cmo.s1590","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20711245","host_type":"repository"},{"url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.354.6143","host_type":""},{"url":"https://doaj.org/article/5a150fbb682244ae99d649a231e4d57c","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2902205","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC2902205","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC2902205?pdf=render","host_type":"Europe_PMC"},{"url":"https://dx.doi.org/10.4137/cmo.s1590","host_type":""}],"fields_of_study":["Renal cell carcinoma treatment","Renal and related cancers","Tuberous Sclerosis Complex Research","0301 basic medicine","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":[],"keywords":["Temsirolimus","Everolimus","Sorafenib","Sunitinib","Discovery and development of mTOR inhibitors","Medicine","Sirolimus","Renal cell carcinoma","PI3K/AKT/mTOR pathway","Oncology","Clinical trial","Internal medicine","Pharmacology","Hepatocellular carcinoma","Biology","Metastatic Renal Cell Carcinoma","Mrcc","Mtor Inhibitors","Neoplasms. Tumors. Oncology. Including cancer and carcinogens","RC254-282"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T07:10:35.933820Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}